Company news

Alamar Biosciences, Inc. news

Latest news releases, newest first.

View company

Alamar Biosciences to Participate in Upcoming Investor Conferences

November 4, 2026

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

November 3, 2026

Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine

November 3, 2026

UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study

November 2, 2026

Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study

November 2, 2026

Emory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar Technology

October 28, 2026

Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026

October 8, 2026

Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team

October 5, 2026

Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment

September 24, 2026

Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

September 1, 2026

Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance

August 10, 2026

Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome

July 28, 2026

Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026

July 14, 2026

Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases

July 12, 2026

Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling

July 10, 2026

Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research

July 7, 2026

Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics

June 2, 2026

Alamar Biosciences Reports First Quarter 2026 Financial Results

May 8, 2026

Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference

May 5, 2026

Alamar Biosciences to Report First Quarter 2026 Financial Results on May 8, 2026

April 30, 2026

Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ

April 19, 2026

Calls

Decks